Home›Trial›NCT05067283
🔬NCT05067283Phase 1RECRUITING

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Study Summary

This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

Conditions
Advanced Solid Tumors
Interventions / Drugs
CalderasibPembrolizumabcarboplatinpemetrexedcetuximaboxaliplatinleucovorin5-fluorouracil
View on ClinicalTrials.gov ↗
Sponsor
MRK
Merck & Co
Oncology/Vaccines
F34/100
Study Details
Enrollment830 participants
Primary Completion—
Lead SponsorMerck Sharp & Dohme LLC
Data Retrieved2026-04-11 02:55:36.206227+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.